TargetMol

Azeliragon HCl

Product Code:
 
TAR-T2507L2
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T2507L2-5mg5mg£850.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T2507L2-50mg50mg£1,661.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T2507L2-100mg100mg£2,079.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Azeliragon is a potent and orally active inhibitor of RAGE (receptor for advanced glycation endproducts), a pattern recognition receptor, which affects the movement of amyloid, an Alzheimer's-associated protein, into the brain.
CAS:
1284150-65-7
Formula:
C32H40Cl3N3O2
Molecular Weight:
605.04
Purity:
0.98
SMILES:
Cl.Cl.CCCCc1nc(cn1-c1ccc(Oc2ccc(Cl)cc2)cc1)-c1ccc(OCCCN(CC)CC)cc1

References

1. Panza F, Seripa D, Solfrizzi V, Imbimbo BP, Lozupone M, Leo A, Sardone R, Gagliardi G, Lofano L, Creanza BC, Bisceglia P, Daniele A, Bellomo A, Greco A, Logroscino G. Emerging drugs to reduce abnormal ?-amyloid protein in Alzheimer's disease patients. Expert Opin Emerg Drugs. 2016 Dec;21(4):377-391. Epub 2016 Oct 6. Review. PubMed PMID: 27678025. 2. Wautier MP, Guillausseau PJ, Wautier JL. Activation of the receptor for advanced glycation end products and consequences on health. Diabetes Metab Syndr. 2016 Sep 4. pii: S1871-4021(16)30208-9. doi: 10.1016/j.dsx.2016.09.009. [Epub ahead of print] Review. PubMed PMID: 27612394. 3. Gody? J, Jo?czyk J, Panek D, Malawska B. Therapeutic strategies for Alzheimer's disease in clinical trials. Pharmacol Rep. 2016 Feb;68(1):127-38. doi: 10.1016/j.pharep.2015.07.006. Epub 2015 Aug 5. Review. PubMed PMID: 26721364.